Pyoderma gangrenosum induced by lenalidomide in a case of multiple myeloma

Meunier, Mathieu; Larabi, Ayoub; Schacherer, Mathilde; Deteix, Clémence; Courby, Stéphane; Cahn, Jean Yves

doi:10.1007/s00277-019-03846-0

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, ND was associated with significantly adverse survival outcomes in patients with MDS in multivariate analyses (hazard ratio, 1.79; 95% CI, 1.03-3.09; P = .04), although other studies found that overall prognosis was more closely related to the IPSS (International Prognostic Scoring System) category than to the underlying autoimmune process . In addition, PG has been reported to be associated with lenalidomide, an immunomodulatory drug that is commonly used to treat MDS, multiple myeloma, and lymphomas, although the exact frequency of PG associated with lenalidomide remains to be determined.…”

Section: Discussionmentioning

confidence: 98%